Margitta Worm spends much of her time researching Allergy, Immunology, Internal medicine, Anaphylaxis and Surgery. Her Allergy research integrates issues from Dermatology, Guideline, Pediatrics and Intensive care medicine. She works mostly in the field of Immunology, limiting it down to concerns involving Disease and, occasionally, Epidemiology.
The various areas that Margitta Worm examines in her Internal medicine study include Placebo, Allergen and Endocrinology. Margitta Worm interconnects Randomized controlled trial and Dupilumab in the investigation of issues within Placebo. In her study, Incidence and Allergists is strongly linked to Systematic review, which falls under the umbrella field of Anaphylaxis.
Her primary areas of study are Immunology, Allergy, Dermatology, Anaphylaxis and Internal medicine. Margitta Worm combines subjects such as Guideline, Provocation test and Asthma with her study of Allergy. Her Dermatology research is mostly focused on the topic Atopic dermatitis.
Her Anaphylaxis research incorporates elements of Epinephrine, Epidemiology, Hypersensitivity reaction and Intensive care medicine. Her biological study deals with issues like Placebo, which deal with fields such as Randomized controlled trial. Her Immunoglobulin E study incorporates themes from Molecular biology and CD40.
The scientist’s investigation covers issues in Anaphylaxis, Allergy, Severe acute respiratory syndrome coronavirus 2, 2019-20 coronavirus outbreak and Internal medicine. Her research in Anaphylaxis intersects with topics in Epinephrine, Family medicine, Intensive care medicine, Vaccination and Pediatrics. Her research integrates issues of Clinical trial and Asthma in her study of Allergy.
Her biological study spans a wide range of topics, including Gastroenterology, Placebo and Atopic dermatitis. The study incorporates disciplines such as Dermatology Life Quality Index, Clinical endpoint, Randomized controlled trial and Eczema Area and Severity Index in addition to Placebo. Her work on Allergen immunotherapy, Immunoglobulin E and Allergen as part of her general Immunology study is frequently connected to Current, thereby bridging the divide between different branches of science.
Margitta Worm focuses on Anaphylaxis, Allergy, Intensive care medicine, Severe acute respiratory syndrome coronavirus 2 and Internal medicine. The study incorporates disciplines such as Reimbursement, Epinephrine, Multivariate analysis, Vaccination and Secondary prevention in addition to Anaphylaxis. Her work carried out in the field of Allergy brings together such families of science as Adverse effect, Asthma, Emergency medicine and Clinical trial.
As part of the same scientific family, Margitta Worm usually focuses on Clinical trial, concentrating on Placebo and intersecting with Severity of illness, Regimen and Eczema Area and Severity Index. Her Internal medicine study frequently links to related topics such as Atopic dermatitis. Her work deals with themes such as Benralizumab and Position paper, which intersect with Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy
A Muraro;T Werfel;K Hoffmann-Sommergruber;G Roberts;G Roberts;G Roberts.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson;Thomas Bieber;Emma Guttman-Yassky;Lisa A. Beck.
The New England Journal of Medicine (2016)
Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology
A. Muraro;G. Roberts;M. Worm;M. B. Bilo.
Impact of gender on asthma in childhood and adolescence: a GA2LEN review.
Almqvist C;Worm M;Leynaert B.
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.
Alain Didier;Hans-Jörgen Malling;Margitta Worm;Friedrich Horak.
The Journal of Allergy and Clinical Immunology (2007)
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor.
D Schadendorf;A Möller;B Algermissen;M Worm.
Journal of Immunology (1993)
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber.
The Lancet (2016)
Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march.
Ingo Marenholz;Renate Nickel;Franz Rüschendorf;Florian Schulz.
The Journal of Allergy and Clinical Immunology (2006)
Direct access to CD4 + T cells specific for defined antigens according to CD154 expression
Marco Frentsch;Olga Arbach;Dennis Kirchhoff;Beate Moewes.
Nature Medicine (2005)
2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.
F. Estelle R. Simons;Motohiro Ebisawa;Mario Sanchez-Borges;Bernard Y. Thong.
World Allergy Organization Journal (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: